» Articles » PMID: 30671182

Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment

Overview
Journal Oman Med J
Specialty General Medicine
Date 2019 Jan 24
PMID 30671182
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Autologous peripheral blood stem cells transplantation (APBSCT) is a therapeutic option which can be used in various hematological, neoplastic disorders including lymphoproliferative disease (LPD). Differences in patient populations and treatment modalities in different transplant centers mean it is important to improve the knowledge of the different factors affecting engraftment after APBSCT for the success of this procedure. We sought to determine the factors influencing neutrophil and platelet engraftment after APBSCT in patients with LPD.

Methods: We conducted a retrospective review of 70 patients with LPD (35 with lymphoma and 35 with multiple myeloma) who had undergone APBSCT between January 2008 and December 2016. Data obtained included disease type, treatment, and stem cell characteristics. Kaplan-Meier analysis was performed for probabilities of neutrophil and platelet engraftment occurred and was compared by the log-rank test. The multivariate Cox proportional hazards regression model was used for the analysis of potential independent factors influencing engraftment. A -value < 0.050 was considered statistically significant.

Results: Most patients were ethnic Malay, the median age at transplantation was 49.5 years. Neutrophil and platelet engraftment occurred in a median time of 18 (range 4-65) and 17 (range 6-66) days, respectively. The majority of patients showed engraftment with 65 (92.9%) and 63 (90.0%) showing neutrophil and platelet engraftment, respectively. We observed significant differences between neutrophil engraftment and patient's weight (< 60/≥ 60 kg), stage of disease at diagnosis, number of previous chemotherapy cycles (< 8/≥ 8), and pre-transplant radiotherapy. While for platelet engraftment, we found significant differences with gender, patient's weight (< 60/≥ 60 kg), pre-transplant radiotherapy, and CD34+ dosage (< 5.0/≥ 5.0 × 10/kg and < 7.0/≥ 7.0 × 10/kg). The stage of disease at diagnosis ( 0.012) and pre-transplant radiotherapy ( 0.025) were found to be independent factors for neutrophil engraftment whereas patient's weight (< 60/≥ 60 kg, 0.017), age at transplantation (< 50/≥ 50 years, 0.038), and CD34+ dosage (< 7.0/≥ 7.0 × 10/kg, 0.002) were found to be independent factors for platelet engraftment.

Conclusions: Patients with LPD who presented at an early stage and with no history of radiotherapy had faster neutrophil engraftment after APBSCT, while a younger age at transplantation with a higher dose of CD34+ cells may predict faster platelet engraftment. However, additional studies are necessary for better understanding of engraftment kinetics to improve the success of APBSCT.

Citing Articles

Predictive factors for engraftment kinetics of autologous hematopoietic stem cells in children.

Andric B, Vujic D, Serbic O, Radonjic Z, Simic M, Kuzmanovic M Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S291-S298.

PMID: 39616107 PMC: 11726089. DOI: 10.1016/j.htct.2024.09.2481.


Analysis of Factors Affecting Hematopoietic Stem Cell Mobilization Efficiency and Early Hematopoietic Reconstruction Indicators during Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation.

Shi H, Duan Y, Bu X Glob Med Genet. 2024; 11(2):159-166.

PMID: 38638371 PMC: 11026139. DOI: 10.1055/s-0044-1786006.


Autologous hematopoietic stem cell transplant at a tertiary care centre in India: achieving comparable outcomes with adaptations.

Gupta A, Meena J, Seth R, Naranje P, Mohanty S, Coshic P Blood Cell Ther. 2024; 7(1):25-32.

PMID: 38486828 PMC: 10937089. DOI: 10.31547/bct-2023-016.


Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation.

Tyrinova T, Batorov E, Aristova T, Ushakova G, Sizikova S, Denisova V Heliyon. 2024; 10(5):e26362.

PMID: 38434301 PMC: 10907647. DOI: 10.1016/j.heliyon.2024.e26362.


Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

Marchesi F, Terrenato I, Papa E, Tomassi M, Falcucci P, Gumenyuk S Ann Hematol. 2024; 103(3):947-956.

PMID: 38189833 PMC: 10867069. DOI: 10.1007/s00277-023-05604-9.


References
1.
Gandhi M, Jestice K, Scott M, Bloxham D, Bass G, Marcus R . The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999; 23(1):9-13. DOI: 10.1038/sj.bmt.1701530. View

2.
Waples J, Moreb J, Sugrue M, Belanger G, Kubilis P, Lynch J . Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant. 1999; 23(9):867-73. DOI: 10.1038/sj.bmt.1701731. View

3.
Jansen J, Thompson E, Hanks S, Greenspan A, Thompson J, Dugan M . Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Bone Marrow Transplant. 1999; 23(12):1251-6. DOI: 10.1038/sj.bmt.1701806. View

4.
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen J . Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 1999; 95(1):7-11. View

5.
Saba N, Abraham R, Keating A . Overview of autologous stem cell transplantation. Crit Rev Oncol Hematol. 2000; 36(1):27-48. DOI: 10.1016/s1040-8428(00)00087-1. View